PolyPid (PYPD) 2024 Sidoti Virtual Micro-Cap Conference summary

Company overview and technology

• Israel-based company with a proprietary drug delivery platform, PLEX, enabling prolonged local drug release for days to months, surpassing competitors' 72–96 hour release.

• PLEX platform is protected by numerous patents and supports multiple products, including a phase III antibiotic (D-PLEX 100) and an oncology program.

• All R&D, clinical, regulatory, and manufacturing operations are integrated and based in Israel.

Lead product and clinical development

• D-PLEX 100, a doxycycline-based product, targets prevention of surgical site infections (SSI) with a 30-day release profile, aligning with CDC definitions.

• SHIELD I, the largest SSI trial in a decade, showed strong infection reduction in high-risk subgroups but missed statistical significance overall due to COVID-era low infection rates.

• Post-hoc and subgroup analyses revealed significant efficacy in large incision and high-risk patients, with up to 54% infection reduction and notable decreases in mortality and reintervention.

• FDA guidance led to SHIELD II, a focused phase III trial in large incision surgeries, with Breakthrough Therapy and Fast Track designations; full enrollment expected by year-end 2024.

• Interim analysis at 400 patients is ongoing, with top-line results for 600 patients expected in Q1 2025; outcomes could include early stop for efficacy or continuation as planned.

Commercial strategy and market opportunity

• U.S. and European addressable markets are substantial, with initial focus on abdominal surgeries; pricing estimated at $800–$1,800 per procedure.

• Commercialization in Europe secured via Advanz Pharma, with a deal valued over $150 million in milestones and royalties; similar partnerships sought for U.S. and other regions.

• Expansion plans include Canada, Latin America, China, and other high-volume or high-price markets, leveraging local partners for regulatory and commercial execution.

• Product eligible for NTAP reimbursement in the U.S., covering up to 75% of drug cost, and aligns with hospital financial incentives to reduce infection-related penalties and costs.